Cutler Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-6,000
| Closed | -$3K | – | 3799 |
|
|
2023
Q1 | $3K | Sell |
6,000
-70,100
| -92% | -$5.81M | ﹤0.01% | 2956 |
|
|
2022
Q4 | $56K | Buy |
76,100
+15,500
| +26% | +$1.23M | ﹤0.01% | 1494 |
|
|
2022
Q3 | $247K | Buy |
60,600
+28,000
| +86% | +$1.77M | 0.02% | 858 |
|
|
2022
Q2 | $59K | Sell |
32,600
-79,500
| -71% | -$4.92M | ﹤0.01% | 1826 |
|
|
2022
Q1 | $382K | Buy |
112,100
+47,100
| +72% | +$3.01M | 0.02% | 793 |
|
|
2021
Q4 | $82K | Buy |
65,000
+43,600
| +204% | +$3M | ﹤0.01% | 2009 |
|
|
2021
Q3 | $46K | Buy |
21,400
+13,400
| +168% | +$941K | ﹤0.01% | 2577 |
|
|
2021
Q2 | $19K | Hold |
8,000
| – | – | ﹤0.01% | 3338 |
|
|
2021
Q1 | $40K | Sell |
8,000
-31,600
| -80% | -$2.04M | ﹤0.01% | 2581 |
|
|
2020
Q4 | $433K | Buy |
39,600
+5,000
| +14% | +$302K | 0.02% | 702 |
|
|
2020
Q3 | $313K | Sell |
34,600
-5,400
| -14% | -$374K | 0.02% | 710 |
|
|
2020
Q2 | $231K | Sell |
40,000
-100
| -0.2% | -$7.66K | 0.02% | 798 |
|
|
2020
Q1 | $283K | Buy |
40,100
+10,200
| +34% | +$705K | 0.01% | 781 |
|
|
2019
Q4 | $296K | Buy |
29,900
+5,000
| +20% | +$326K | 0.02% | 647 |
|
|
2019
Q3 | $319K | Sell |
24,900
-2,700
| -10% | -$176K | 0.03% | 498 |
|
|
2019
Q2 | $276K | Sell |
27,600
-11,900
| -30% | -$783K | 0.03% | 556 |
|
|
2019
Q1 | $380K | Sell |
39,500
-32,900
| -45% | -$2.19M | 0.04% | 407 |
|
|
2018
Q4 | $303K | Buy |
72,400
+3,700
| +5% | +$259K | 0.03% | 478 |
|
|
2018
Q3 | $62K | Sell |
68,700
-11,900
| -15% | -$899K | ﹤0.01% | 1472 |
|
|
2018
Q2 | $279K | Buy |
80,600
+9,200
| +13% | +$650K | 0.02% | 644 |
|
|
2018
Q1 | $268K | Sell |
71,400
-31,300
| -30% | -$2.49M | 0.02% | 662 |
|
|
2017
Q4 | $464K | Buy |
102,700
+100
| +0.1% | +$7.59K | 0.02% | 574 |
|
|
2017
Q3 | $379K | Buy |
102,600
+28,900
| +39% | +$2.21M | 0.01% | 803 |
|
|
2017
Q2 | $286K | Sell |
73,700
-360,900
| -83% | -$24M | 0.01% | 1026 |
|
|
2017
Q1 | $1.6M | Buy |
434,600
+398,400
| +1,101% | +$28M | 0.07% | 246 |
|
|
2016
Q4 | $455K | Sell |
36,200
-153,900
| -81% | -$11.4M | 0.02% | 742 |
|
|
2016
Q3 | $2.55M | Buy |
190,100
+59,900
| +46% | +$4.87M | 0.11% | 132 |
|
|
2016
Q2 | $2.14M | Sell |
130,200
-25,500
| -16% | -$2.26M | 0.11% | 136 |
|
|
2016
Q1 | $1.73M | Sell |
155,700
-107,300
| -41% | -$9.68M | 0.11% | 145 |
|
|
2015
Q4 | $917K | Buy |
+263,000
| New | +$27.4M | 0.05% | 363 |
|
Other funds holding GILD
Cutler Group's GILD Position: Q1 2023 in Review
Cutler Group sold out of Gilead Sciences (GILD) in Q1 2023, closing a stake of 20,570 shares — an estimated $1.7M sold.
Cutler Group first reported a position in GILD in Q4 2015 and held it in 27 quarters. The position peaked at $17.9M in Q2 2016. 1,735 funds tracked by Wall St. Rank hold GILD as of Q1 2023.
- Cutler Group reported no remaining Gilead Sciences position as of Q1 2023 after selling out during the quarter.
- Cutler Group sold 20,570 Gilead Sciences shares in Q1 2023, an estimated $1.7M.
- Cutler Group first reported a position in Gilead Sciences in Q4 2015 and held it in 27 quarters.
- Cutler Group's Gilead Sciences position peaked at $17.9M in Q2 2016.
- 1,735 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2023.
Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.